89 related articles for article (PubMed ID: 6299267)
21. 6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
Maslen HL; Hughes D; Hursthouse M; De Clercq E; Balzarini J; Simons C
J Med Chem; 2004 Oct; 47(22):5482-91. PubMed ID: 15481985
[TBL] [Abstract][Full Text] [Related]
22. Herpes simplex virus-1 and varicella virus infections in familial dysautonomia patients.
Maayan C; Nimrod A; Morag A; Becker Y
J Med Virol; 1998 Mar; 54(3):158-61. PubMed ID: 9515762
[TBL] [Abstract][Full Text] [Related]
23. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
25. Immunochemical characterization of pyrimidine kinase induced by varicella-zoster virus.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
J Gen Virol; 1985 Feb; 66 ( Pt 2)():221-9. PubMed ID: 2981965
[TBL] [Abstract][Full Text] [Related]
26. In-vitro synthesis of functional varicella zoster and herpes simplex viral thymidine kinase.
Mahalingam R; Cabirac G; Wellish M; Gilden D; Vafai A
Virus Genes; 1990 Jul; 4(2):105-20. PubMed ID: 1698324
[TBL] [Abstract][Full Text] [Related]
27. Virus type-specific thymidine kinase in cells biochemically transformed by herpes simplex virus types 1 and 2.
Davis DB; Munyon W; Buchsbaum R; Chawda R
J Virol; 1974 Jan; 13(1):140-5. PubMed ID: 4359421
[TBL] [Abstract][Full Text] [Related]
28. Latency and reactivation of varicella zoster virus infections.
Dueland AN
Scand J Infect Dis Suppl; 1996; 100():46-50. PubMed ID: 9163025
[TBL] [Abstract][Full Text] [Related]
29. Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
Véron JB; Allouchi H; Enguehard-Gueiffier C; Snoeck R; Andrei G; De Clercq E; Gueiffier A
Bioorg Med Chem; 2008 Nov; 16(21):9536-45. PubMed ID: 18835175
[TBL] [Abstract][Full Text] [Related]
30. The use of herpes virus induced dTk as a marker for serological and direct identification of herpes virus infection in man.
Gronowitz JS; Källander CF
Dev Biol Stand; 1982; 52():193-204. PubMed ID: 6299830
[TBL] [Abstract][Full Text] [Related]
31. A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons.
Gershon AA; Chen J; Gershon MD
J Infect Dis; 2008 Mar; 197 Suppl 2():S61-5. PubMed ID: 18419411
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection.
Giehl KA; Müller-Sander E; Rottenkolber M; Degitz K; Volkenandt M; Berking C
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):722-8. PubMed ID: 18312326
[TBL] [Abstract][Full Text] [Related]
33. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
34. Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses.
Andrei G; van den Oord J; Fiten P; Opdenakker G; De Wolf-Peeters C; De Clercq E; Snoeck R
Antimicrob Agents Chemother; 2005 Nov; 49(11):4671-80. PubMed ID: 16251311
[TBL] [Abstract][Full Text] [Related]
35. Key issues in varicella-zoster virus latency.
Kennedy PG
J Neurovirol; 2002 Dec; 8 Suppl 2():80-4. PubMed ID: 12491156
[TBL] [Abstract][Full Text] [Related]
36. Focus assay for varicella-zoster virus in human embryo cells stained with immunoperoxidase method.
Schmidtmayerová H; Mayer V; Zachar V
Acta Virol; 1986 Nov; 30(6):468-74. PubMed ID: 2881466
[TBL] [Abstract][Full Text] [Related]
37. Studies on the polypeptides of varicella-zoster (V-Z) virus. II. Syntheses of viral polypeptides in infected cells.
Asano Y; Takahashi M
Biken J; 1980 Sep; 23(3):95-106. PubMed ID: 6257229
[TBL] [Abstract][Full Text] [Related]
38. Transfer of thymidine kinase to thymidine kinaseless L cells by infection with ultraviolet-irradiated herpes simplex virus.
Munyon W; Kraiselburd E; Davis D; Mann J
J Virol; 1971 Jun; 7(6):813-20. PubMed ID: 4327589
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and immunological characterization of deoxythymidine kinase of thymidine kinaseless HeLa cells biochemically transformed by herpes simplex virus type.
Cheng YC; Chadha KC; Hughes RG
Infect Immun; 1977 May; 16(2):486-92. PubMed ID: 193790
[TBL] [Abstract][Full Text] [Related]
40. Regulation of thymidine kinase activity in mouse L cells biochemically transformed by varicella-zoster virus.
Shiraki K; Mori H; Hayakawa Y; Yamanishi K; Takahashi M
Microbiol Immunol; 1989; 33(8):693-8. PubMed ID: 2550747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
